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Stem Cell Treatments on the WebA report by the International Society for Stem Cell Research (ISSCR)’s Task Force on Unproven Stem Cell
Treatments outlines development of resources for patients, their families, and physicians seeking informa-
tion on stem cell treatments.Introduction
The International Society for Stem Cell Research (ISSCR) is con-
cerned that stem cell treatments are being marketed to
consumers around the world without safeguards in place to
ensure the safety or likely effectiveness of experimental treat-
ments or truthfulness of claims about so-called proven thera-
pies. These practices could place individual patients at risk
and also jeopardize the progress of legitimate stem cell clinical
translation. The ISSCR seeks to alert patients and their care-
givers to these potential concerns and to answer the numerous
enquiries received from patients and their advocates about
clinics that claim to offer stem cell therapies.
The ISSCR Task Force on Unproven Stem Cell Treatments
(hereafter the Task Force) was convened by the 2009–2010
President of the ISSCR, Dr. Irving Weissman, to formulate
recommendations for the development of a web-based resource
for patients, their advocates, clinicians, and associations in eval-
uating claims of benefit from advertised stem cell treatments. In
particular, the Task Force was asked to propose a process for
listing clinics or programs and whether they meet what the
ISSCR deems to be minimum standards of assessing safety
and efficacy and to define criteria to systematically evaluate
clinics or programs for inclusion on such a list (Weissman,
2009). The members of the Task Force are listed in Table S1.
Here, we summarize the discussion and recommendations of
the Task Force for the development of a web-based resource
that includes: (1) listing of individuals, clinics, or other entities
offering asserted stem cell therapies and whether they provide
information showing that appropriate safeguards are in place;
(2) resources that explain fundamental scientific principles of
stem cell biology and the implications for stem cell treatments
and outline the widely accepted process of clinical translation;
and (3) a list of questions patients and caregivers should ask
purveyors to aid them in making treatment decisions.
Why an ISSCR Initiative on Unproven Stem Cell
Treatments?
The extraordinary promise of stem cells for future treatments of
otherwise intractable diseases and conditions has raised great
hope and expectations in patients, advocates, physicians, and
researchers alike. Yet this excitement has led to unacceptable
exploitation of patients’ hopes and fears.
Through literature, clinician reports, patient questions, and
patient complaints, the problem of misleading direct-to-
consumer advertisement of stem cell therapies has become all
too familiar to members of the Task Force, the ISSCR, local
stem cell networks, and patient advocate organizations dedi-
cated to disease-specific cures. Advertisements that claim tooffer proven and effective therapies for many diseases have
sprung up in various forms relying on doubtful theories that
neither peer nor public review, nor regulatory authorities, have
verified. Indeed, a study of advertising on widely accessed web-
sites demonstrated that the portrayal of likely clinical benefit is
optimistic, overpromising results and underestimating the
potential risks, and is unsubstantiated by peer-reviewed litera-
ture available to all scientists, medical professionals, and
laypeople (Lau et al., 2008). Clinical outcome may be selectively
displayed, methods kept secret and not subjected to indepen-
dent scientific and clinical examination, and treatment offered
outside of regulatory oversight. These so-called therapies there-
fore fail to meet minimum ethical, scientific, and medical stan-
dards that such oversight entails, including appropriate support
through preclinical data; commensurability of risks and benefits;
phased, structured assessment of safety, efficacy, dosing, or
appropriate administration; and independently assessed and
approved informed consent.
Furthermore, in some situations, large amounts of money are
being charged for apparently unsubstantiated therapies, a further
departure from widely accepted norms. Authorization to market
a medicinal product is typically sought from a national or supra-
national regulatory agency only after rigorous testing through
a formal process of clinical trials has established safety and effi-
cacy. In a formal clinical trial setting, it is not common practice for
the provider to charge for the experimental treatment, rather
costs of the experimental treatment and trial monitoring is often
defrayed by the company developing the treatment or by local or
national government funding.
A problem of these dimensions calls for more than the actions
of any one organization or agency, and certainly more than the
actions of one scientific society such as the ISSCR. Yet, the
ISSCR recognizes the essential relationship that exists between
scientific progress and public responsibility. In previous reports
(‘‘Guidelines for the Conduct of Human Embryonic Stem Cell
Research’’ and the ‘‘Guidelines for the Clinical Translation of
Stem Cells’’), the ISSCR addressed the broader social, ethical,
and legal implications in addition to setting professional stan-
dards for research conduct and clinical application (Daley
et al., 2007; ISSCR, 2006; ISSCR 2008a; Taylor, 2007; Hyun
et al., 2008). The latter guidelines include a stand-alone
appendix, a ‘‘Patient Handbook on Stem Cell Therapies’’ to
directly address the concerns of patients (ISSCR, 2008b).
This current effort therefore grows out of the long-standing
commitment of the ISSCR to ethical and scientific self-regulation
through globally representative consensus on standards that
distinguish sound and ethical stem cell science from practices
that would be unethical or unsound. The Task Force believesCell Stem Cell 7, 43–49, July 2, 2010 ª2010 ISSCR 43
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tions and the public to address social, ethical, and legal implica-
tions of scientific progress. The ISSCR’s aspirations for public
benefit through increasing knowledge entail this commitment:
to avoid overstating what is currently known, whether in the
scientific domain, the clinical domain, or the commercial domain.
In fact, clinics and suppliers making unproven or exaggerated
claims may endanger patients, and through poor or reckless
practice they potentially discredit the field itself and threaten to
impede the progress of legitimate clinical translation. The Task
Force believes that the ISSCR has an appropriate role in working
with others to address such clinics and suppliers and to educate
professionals and patients as to responsible pathways of clinical
translation. We therefore endorse the President’s initiative and
commend the ISSCR for its willingness to undertake such a step.
The ISSCR is a scientific and medical society with unique
knowledge of a still-developing scientific frontier and specialized
expertise in the necessarily careful pathway from basic scientific
knowledge to patient benefits through responsible clinical trans-
lation. The Task Force members reflect this expertise and have
brought to this effort a great diversity of perspectives—
researchers, clinicians, ethicists, jurists, and patient advocates.
The Task Force provides the recommendations within this report
after much discussion and consideration, for the establishment
of a feasible methodology for ISSCR action while maximizing
the value of information made available to patients and their
advocates.2008 ISSCR Guidelines: Defining the Appropriate
Pathway from Basic Scientific Knowledge
to Clinical Applications
The ISSCR published ‘‘Guidelines for the Clinical Translation of
Stem Cells,’’ which define a pathway for the responsible develop-
ment of safe and effective stem cell therapies (ISSCR 2008a). In
that report, the Task Force on the Clinical Translation of Stem
Cells recommended that development of stem cell therapies
occur primarily through structured clinical research trials, which,
under internationally accepted standards, are subject to inde-
pendent and ongoing assessment of their scientific and ethical
soundness by ethical review boards and government agencies.
These guidelines recognized that progress, especially in
surgical treatment, has occurred through innovation outside clin-
ical research trials (Section 7: Stem Cell-Based Medical Innova-
tion). However, respect for innovation has never meant that
patients’ urgent needs justify scientifically reckless or unethical
acts. Innovation outside research requires, among other things,
that the scientific and clinical plausibility for an innovative
approach is demonstrable; that patients can weigh known and
possible risks against realistic descriptions of potential benefits;
that alternative treatments are clearly communicated; that there
is independent review and oversight; and that clinical supports
are in place to address known and unanticipated risks. The
guidelines also noted that certain characteristics of stem cells
required that their development as medical interventions called
for special care and ‘‘underscore the need for independent
expert peer review prior to clinical investigation to ensure the
integrity of the research and informed consent processes’’
(Section 1: Introduction).44 Cell Stem Cell 7, 43–49, July 2, 2010 ª2010 ISSCRThe Task Force on the Clinical Translation of Stem Cells felt
strongly that the innovation exception does not justify the
commercialization of stem cell-based interventions without cred-
ible rationale or oversight or without a commitment by practi-
tioners to use this experience to contribute to a general body of
knowledge through the communication of outcomes, including
negative outcome or adverse events, to the scientific community
for critical review and by moving to a formal clinical trial in a timely
manner. Indeed, the guidelines ‘‘recognize[d] a distinction
between the commercial purveyance of unproven stem cell inter-
ventions and legitimate attempts at medical innovation outside
the context of a formal clinical trial. Responsible clinician-scien-
tists may have an interest in providing medically innovative care
to a few patients using stem cells or their derivatives prior to
proceeding to a formal clinical trial,’’ and the peer-reviewed
scientific and medical case, together with the patient’s informed
choice among limited alternatives, may justify it in certain cases.
The Task Force on the Clinical Translation of Stem Cells there-
fore concluded, and the ISSCR Board of Directors agreed, that
the primary pathway for translating scientific advances into ther-
apies ought to be the well-established route from peer-reviewed
science to ethically and scientifically reviewed clinical research
trials under appropriate regulatory oversight.
Defining the Problem
To establish which aspects of medical practice might be as-
sessed by objective review and examination of publicly available
materials and direct contact, and what kind of information might
be useful to those seeking treatments, the Task Force first dis-
cussed concerns about the commercial practice of unproven
stem cell interventions.
We eliminated aspects of practice that do not represent the
primary problem. First, we noted that the concern is not about
medical tourism in which citizens of one country travel to another
country for treatments offered uniquely or more cheaply. The
problem of unproven stem cell treatments occurs in many coun-
tries, and whether abroad or at home, the absence of essential
clinical supports and follow-through can expose patients to
serious health risks. Thus, although some medical tourism raises
special concerns, and some issues with questionable clinics and
suppliers involve medical tourism, the problems are not identical
nor necessarily coincident (Cohen, 2010).
The concern is also not simply the attempt to treat diseases for
which there is no scientifically proven stem cell-based thera-
peutic solution. This view of the problem is too broad, for it would
treat legitimate clinical research as being identical to the sale of
unproven treatments. Furthermore, to simply define treatable
and untreatable conditions and to use this as a criterion for listing
a given entity would require the ISSCR to be omniscient with
respect to all new developments, including proprietary ones.
A fundamental principle espoused by previous ISSCR guide-
lines and reiterated by this Task Force is transparency: a willing-
ness to communicate openly with the scientific and medical
community, with regulators and with patients. This task force
had enormous concern about medical practices where evidence
of this communication was missing—where there was a lack of
openness concerning methods and results, lack of peer review,
inaccurate portrayal of scientific plausibility, unclear expertise of
practitioners, and lack of independent oversight. These issues
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those who would base their choice on scientific and ethical
soundness, but also those who, less persuaded by such factors
given the failure of existing therapies, would nonetheless be con-
cerned with the truthfulness of solicitations with their own
medical vulnerability to matters becoming even greater through
unknown risks and unaddressed adverse events.
We see a widely accepted imperative to report research and
clinical findings and to subject results, methodologies, and
conclusions to the scrutiny of independent experts in the field.
The practice of external peer review has long been held as the
foundation of biomedical publication and used as a method to
assess the rigor of scientific enquiry and to minimize unwarranted
claims or overinterpretation of data prior to broad circulation.
Replication of data by independent groups is a key indicator
that the data are robust— that the findings and conclusions are
likely to be valid and that the technology can be repeated in
someone else’s hands. Thus, robustness of data might be evalu-
ated by (1) direct relevance of the data to the specific disease and
treatment in question; (2) publication by groups working indepen-
dently of each other; (3) publication of results, methodologies, and
conclusions; and, (4) as an indication of peer review and basic
scientific quality, inclusion in the MEDLINE database, a freely
available and well-recognized database of articles from journals
that observe prescribed publication procedures compiled by the
United States National Library of Medicine (NLM) (US NLM, 2007).
The Task Force also affirmed previous statements and reports
from the ISSCR and other international bodies that only when
compelling preclinical data are available is careful and incre-
mental testing in patients justified, and then such testing is
always subject to rigorous and independent scientific and ethical
oversight.
Through these deliberations, the Task Force identified core
elements that reflect a commitment to transparency in opera-
tions and a commitment to the widely recognized translational
trajectory noted above. These elements do not incorporate all
criteria identified as important by the Task Force for assessing
safety and likely efficacy. They do, however, provide an objective
minimum level of transparency of practice and independent
scientific, ethical, and regulatory oversight.
1. The clinical investigations from the early trials to commer-
cialization have been conducted under the guidance and
authority of an independent oversight body that adheres
to internationally accepted ethical guidelines for the
protection of human subjects, including assessment that
the risk to patients was not greater than the possible bene-
fits and that the patient or the patient’s parents or legal
guardians understood and gave informed consent for the
medical procedure to take place.
2. The clinical investigations from the beginning to commer-
cialization have been overseen and authorized by
a national or supranational regulatory body or bodies for
safety and efficacy.Recommendations
Inquiry and Review Process
The Task Force recommends that the ISSCR establish an
inquiry and review process to look into clinics and supplierspromising therapeutic benefits from the administration of prep-
arations claimed to contain or be constituted of stem cells and/
or their induced derivatives. The guiding principles for the
development of the recommended process were that (1) the
standards for identifying and reviewing clinics and suppliers
should be objective and clear; (2) the inquiry and review
process should be publicly transparent and relatively straight-
forward for any clinic or practitioner to comply with; (3) conflicts
of interest, if any, of the declarant ought to be disclosed to the
ISSCR; (4) there should be no actual or apparent conflicts of
interest of staff or others involved in the inquiry or review
process for any particular matter; and (5) any findings that
a clinic fails to meet standards should be communicated in
a specific factual way, rather than with broad conclusions of
fraudulent practices.
Four main steps are outlined for the inquiry process:
1. Identification of the clinics to be contacted about their
practices. The process should be open to identification
of entities for examination from a broad and unbiased
range of sources, such as patients and external groups
and requests by ISSCR members. Inquiry should be pur-
suant to a standardized online intake process, such as
that on the draft intake form (Figure S1 available online).
2. Preliminary review of advertising and solicitation materials
of the clinic or supplier, such as Web materials, to deter-
mine whether the entity is involved in or claims to be
involved in the purveyance of stem cell therapy, or the
supply of stem cells or other stem cell-related service
where there is claim/implication of therapeutic benefit.
3. Contact with the clinic or supplier to request information
aligned with the elements of inquiry discussed below
(see Figure 1). The entity will be subjected to scrutiny for
each disease encountered on the advertising or solicita-
tion materials. At the time of this publication, entities will
be excluded from the search in which the information
available is not provided in English or lacks a translation
into English. The Task Force recommends translations of
advertising materials to English be incorporated into the
inquiry process over time. Entities will also be excluded
from the search in which the only clinical applications cited
are (1) bone marrow, cord blood, or other blood stem cell
populations used to treat diseases/conditions of the
blood-forming or immune systems (including the treat-
ment for compromised hematopoiesis secondary to high
dose chemotherapy for cancers) or (2) epidermal stem
cell therapies for burn trauma or limbal stem cells for
corneal replacement.
4. Review and results publication. Materials received will be
reviewed as objectively as possible against the inquiry
elements, discussed below. The meaning of the results
ought to be self-evident from a clear description on the
ISSCR Web site of the precise processes and criteria
used. Interpretation and subjective conclusions should
be avoided in any presentation of the data.Elements of Inquiry
The Task Force recommends that the inquiry and review process
ask for evidence that the entity under review adheres to theCell Stem Cell 7, 43–49, July 2, 2010 ª2010 ISSCR 45
Is the individual clinic or enty oﬀering or claiming to oﬀer 
an intervenon that uses stem cells or their derivaves?
Is the enty 
claiming or 
implying a 
therapeuc use?
Is the enty 
oﬀering another 
stem cell related 
service?
Is the enty supplying or 
claiming to supply stem cells or 
their derivaves?
Is there evidence of 
human protecon 
oversight? 
Is there evidence of 
naonal regulatory 
oversight?
no to
either
yes to
both
The ISSCR may also supply references subject to the 
same qualiﬁcaons as outlined above that may 
provide either a supporve or counter argument
Informaonal
elements of inquiry
Determining
elements of inquiry
Exit
Exit
Proceed to 
direct
inquiry
1-2 peer reviewed
papers
demonstrang
scienﬁc principles
available on
Medline
no
no
no no no
yes
yes yes yes
yes
1-2 peer reviewed
papers describing 
outcome of human
clinical trials
available on
Medline
Enty is listed as
UNDOCUMENTED
Enty is listed as
DOCUMENTED
-
forming or immune systems, 
epidermal stem cell therapies for 
burns or limbal stem cell 
Figure 1. Schematic of Inquiry and Review
Process for Listing Stem Cell Treatment
Providers
The inquiry and review process recommended by
the task force is depicted graphically (see text for
details). A preliminary review of advertising mate-
rials brought to the attention of the ISSCR will
determine whether a direct inquiry will be made
to the entity. Entities advertising stem cell treat-
ments or claiming clinical efficacy of stem cell
products for applications outside of the blood
system, epithelial stem cell treatments for burns,
or limbal stem cell treatments for corneal repair
will be asked for evidence that (1) a medical ethics
committee was involved to protect patients’ rights
and (2) appropriate regulatory oversight was in
place. The entity will be listed as ‘‘documented’’
or ‘‘undocumented’’ on the basis of whether or
not they provide these elements. Undocumented
clinics that claim to be practicing innovative medi-
cine will be listed with a statement indicating the
ISSCR Task Force position on innovative medicine
(see text for details). Citations to relevant literature
may be included with the Web site listing; the entity
is invited to provide relevant robust publications
and the ISSCR may also provide such publications
offering a supportive or counter argument. See
also Table S1 and Figure S1.
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clinical applications. The following elements do not incorporate
all of the important criteria identified by the Task Force for as-
sessing safety and likely efficacy, nor do they allow the judgment
of relative anticipated effectiveness. They do, however, provide
an objective minimum level of transparency of practice and inde-
pendent review.
Determining Elements of Inquiry. Clinics and suppliers should
be asked to provide evidence of the following for a given treat-
ment for a given disease or condition offered in the context of
a research study (clinical trial), experimental therapy, or claimed
proven therapy:
1. Evidence of review and approval for human subjects
protection by an independent committee or agency such
as an Institutional Review Board or Ethics Review
Committee established under internationally accepted
ethical guidelines; including at a minimum:
d Name of applicant/principal investigator
d Title of protocol/project
d Committee name and/or identifying number
d Date of approval
d Name of signing individual
d Contact information for signing individual46 Cell Stem Cell 7, 43–49, July 2, 2010 ª2010 ISSCRThe ISSCR may contact the signing
individual identified in an effort to confirm
that the applicant, protocol/project, and
approval are asserted accurately.
2. Review and authorization or
approval by relevant supranational
or national regulatory authoritiessuch as the European Medicines Agency (EMA) or the
US Food and Drug Administration (FDA) for clinical trial
or, where applicable, reimbursed therapies/commercial
use based on data provided by the clinic or others under
supervised trials; or evidence of exemption from review.
The ISSCR may contact the relevant regulatory authority in an
effort to confirm that the information provided is complete and
accurate.
These determining elements of inquiry stated above—review
for human subjects protection and regulatory oversight—should
direct the ISSCR in listing clinics.
Informational Elements of Inquiry. Clinics and suppliers should
be invited to submit to the ISSCR examples of preclinical and
clinical research published in the peer-reviewed literature:
1. Up to two published articles from groups, ideally working
independently of each other, demonstrating the scientific
principles for use of a given cell product for the specific
disease.
2. Up to two published articles demonstrating the outcome
of human clinical trials for both safety and efficacy.
Articles should be peer reviewed, include data of direct rele-
vance to the specific disease in question, include results,
Cell Stem Cell
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included in the MEDLINE database. The entire article should
be provided to the ISSCR.
Output—A Web-Based Resource
The Task Force recommends a web-based resource that
includes the parts outlined below. Together, these should allow
a patient on their own, or in consultation with their health care
provider, to consider whether the approach taken by a clinic of
interest might lack the scientific rigor, transparency, and inde-
pendent oversight and regulation the ISSCR and others advo-
cate.
1. An online intake mechanism. A brief form that can be used
by any individual to submit an entity to the ISSCR for
formal inquiry.
2. Results of inquiry. The Task Force recommends two list-
ings be developed that separately include those entities
that do and do not provide upon request evidence of
both of the above determining criteria (review for human
subjects protection and regulatory oversight) in a timely
manner and on a disease-by-disease basis. A review will
be made for each disease encountered on the advertising
or solicitation materials, except where excluded as out-
lined in the inquiry process. Thus, an entity may be
included on a given list multiple times or for only a subset
of the diseases for which they claim a stem cell-based
treatment. The names of clinics currently under review
will not be disclosed.
The information used for the inclusion of an entity on one or the
other of these lists is provided by that entity. The ISSCR will not
be responsible for the accuracy of claims.
A. Listing of clinics that do not provide evidence of both
human subjects and regulatory oversight (the determining
inquiry elements): ‘‘undocumented.’’ Those entities that
do not provide the information pertaining to human
subjects and regulatory oversight requested of them
should be listed as ‘‘undocumented.’’ The listing will be
prefaced with an explanatory statement that describes
the process and clearly indicates that:i. The listing of an entity does not imply either ISSCR
approval or disapproval, rather that specific elements
of inquiry have not been adequately addressed.
ii. Similarly, absence of an entity or removal of an entity
from listing does not imply ISSCR approval.
iii. No conclusion can be drawn from the absence of an
entity/disease from this listing as the process is such
that if an entity is not listed it may mean one of three
very different things: no inquiry has been made; the
inquiry is still in process; or the clinic has addressed
each of the elements of inquiry.If an entity is listed here and then subsequently provides infor-
mation that addresses missing required elements, its name will
be removed from this listing. Where the entity responds that
they no longer offer treatment for a disease that has been previ-
ously advertised or offered, its name will be removed from this
listing but a footnote will be included that the clinic no longer
treats this disease. Entities that do provide evidence of both ofthe determining elements of inquiry requested will be included
on an independent listing as outlined below.
B. Listing of clinics that do provide evidence of the deter-
mining inquiry elements: ‘‘documented.’’ Where evidence
is provided that both human subjects and regulatory over-
sight are in place, clinics will be listed as ‘‘documented.’’
Again, this listing should in no way imply either ISSCR
approval or disapproval, rather that the information re-
quested has been provided. Thus, as for the previous
listing, no conclusion can be drawn from the absence of
an entity/disease from this listing as the process is such
that if an entity is not listed it may mean one of three
very different things: no inquiry has been made, the inquiry
is still in process, or the clinic did not provide evidence to
satisfy that both elements were addressed.
Approval by the appropriate independent human subjects
oversight body and regulatory agency reflects only that certain
ethical and legal obligations, respectively, have been met in
the given locale. There is significant global diversity in what
circumstances a regulatory agency may grant approval or
provide exemption of review for a given product and what
processes and standards are applied during review. Assessment
of when a particular therapy is ready to move into clinical trials or
from clinical trials to a more widely available treatment outside of
trials may take into account a range of factors not necessarily
applicable to other regions including the current standard of
care treatment or prevalence of a disease or condition in the local
population.
To provide additional information for caregivers or others
interested, the listing will document relevant publications
provided by the entity as outlined above (‘‘Informational
Elements of Inquiry’’). Citations will be provided or, where the
paper may be freely disseminated without breach of copyright,
a pdf copy may be attached. The ISSCR may also supply up to
two references subject to the same publishing qualifications
outlined above that may provide either a supportive or counter
argument.
There is necessarily a significant period of time from when the
intake sheet is filled out requesting the ISSCR investigate
a specific clinic until a final determination is made, estimated
at 4–5 months. The Task Force recognizes that, particularly at
the beginning before they are well established, the data listings
will not address the concerns of an individual patient or their
advocates looking to make immediate decisions. In addition,
the criteria assessed do not address the complexities of informa-
tion needed for an individual medical decision, although their
absence portends a failure to respect known, widely accepted,
fundamental standards.
Therefore, we recommend that the following resources be
included on the Web site.
3. Resources that explain fundamental scientific principles of
stem cell biology and the implications for stem cell treat-
ments and outline the widely accepted process of clinical
translation. Understanding key aspects of stem cell
biology and what is realistic to expect from stem cell treat-
ment might aid a patient and their caregiver in determiningCell Stem Cell 7, 43–49, July 2, 2010 ª2010 ISSCR 47
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example, tissue-specific stem cells are limited in their
potential and largely form the cell types found in the tissue
from which they are derived. Thus, it is unlikely that a single
cell type could be used to treat a multitude of unrelated
diseases that involve different tissues or organs, and
a patient should be wary of a clinic that makes such
claims. Likewise, understanding the implementation of
clinical trials and ultimately the commercial availability of
a medicinal product, and the provisions for patient protec-
tion demanded by ethical oversight committees and regu-
latory bodies throughout this process, might make clear
where there are concerning departures from widely
accepted practice. For example, high cost of an experi-
mental treatment might raise an immediate red flag to
consumers that very careful investigation is required.
4. Further questions a patient, if possible working with their
caregiver, should ask the provider as part of evaluating
the clinic and treatment they are considering. Transpar-
ency and forthrightness are owed to any patient consid-
ering a potential therapy; indeed without it there can be
no actual informed consent. A potential patient ought to
be able to consult their own personal caregiver before
making a choice and involve their own local caregiver in
after-care if they wish. Furthermore, for any patient, even
a patient undergoing well-accepted therapy, the clinical
environment is critical. The list of questions provided by
this document should assist a patient in evaluating such
parameters.
Innovative Medicine Statement
The Task Force on Unproven Stem Cell Treatments agreed with
the recommendations for practicing innovative medicine made
by the ISSCR’s Task Force on Clinical Translation of Stem Cells
that application of medical innovation in the stem cell field should
be confined to a very limited number of cases, should be sub-
jected to external review and stringent oversight, and should
move quickly toward a formal research study. Indeed, this
Task Force argued that medical innovation be limited to no
more than two participants. Therefore, we recommend that if
the entity advertises an experimental or innovative medicine,
the same inquiry process be applied.
Whether in advertising or solicitation materials, or in response
to the ISSCR’s inquiry, if an entity states that a therapy being
offered is experimental or innovative and therefore does not
need to have been tested in clinical trials or does not need the
human subjects protection or regulatory oversight, the clinic
will be listed with the following annotation:
The position of the ISSCR Task Force is that the provision
of an untested experimental or innovative therapy to more
than two participants is a departure from recommended
practice and should be tested in a regulated and autho-
rized clinical trial prior to being offered for sale.
Outreach
The Task Force recommends that its report be publicly pre-
sented. Posting of this report on the ISSCR Web site and through
the ISSCR pages of affiliated journal Cell Stem Cell have both
been useful devices in the past, and we endorse them here.48 Cell Stem Cell 7, 43–49, July 2, 2010 ª2010 ISSCRIn addition, we recommend active engagement of other stem
cell networks and consortiums and patient advocacy groups that
could play a key and complementary role in disseminating infor-
mation on this and other work that addresses fraudulent clinics
or suppliers of stem cells and in framing the combined set of
actions in a way that is understandable and useful to patients
and to those who will receive their queries and requests for help.
The ISSCR should offer the educational resources and infor-
mation offered on the Web site in additional languages wherever
possible. To date, working with stem cell network partners, the
ISSCR offers the ‘‘Patient Handbook on Stem Cell Therapies’’
in English, German, Italian, and French. Japanese and Spanish
translations are planned.
We also strongly support working with the press in various
countries to explain the problem, the approach we take, the
potential role of other partners, and, indeed, the potential role
the press itself could play in helping all of us avoid hyped discus-
sion of stem cell ‘‘therapies.’’
This concludes the recommendations of the Task Force.
SUPPLEMENTAL INFORMATION
Supplemental Information includes one table and one figure and can be found
with this article online at doi:10.1016/j.stem.2010.06.001.
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